Enanta Pharmaceuticals (ENTA) Other Non-Current Liabilities (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Other Non-Current Liabilities of $278000.0 for Q1 2026, up 14.4% year-on-year from $243000.0 in Q1 2025, and up 3.35% on a QoQ basis from $269000.0 in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of Other Non-Current Liabilities data on file, last reported at $278000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 14.4% year-over-year to $278000.0; the trailing twelve-month figure through Mar 2026 stood at $278000.0 (up 14.4% YoY), and the FY2025 full-year result was $260000.0, up 12.55% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $278000.0, up from $269000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.4 million in Q3 2022 and bottomed at $224000.0 in Q1 2024.
- The 5-year median for Other Non-Current Liabilities is $278000.0 (2026), against an average of $450705.9.
- The widest annual swing landed in 2023, when Other Non-Current Liabilities jumped 56.76%; it then sank 83.77% in 2024.
- A 5-year view of Other Non-Current Liabilities shows it stood at $414000.0 in 2022, then soared by 56.76% to $649000.0 in 2023, then plunged by 63.79% to $235000.0 in 2024, then gained by 14.47% to $269000.0 in 2025, then increased by 3.35% to $278000.0 in 2026.
- The last three Other Non-Current Liabilities figures came in at $278000.0 (Q1 2026), $269000.0 (Q4 2025), and $260000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 278,000.00 |
| Dec 31, 2025 | 269,000.00 |
| Sep 30, 2025 | 260,000.00 |
| Jun 30, 2025 | 252,000.00 |
| Mar 31, 2025 | 243,000.00 |
| Dec 31, 2024 | 235,000.00 |
| Sep 30, 2024 | 231,000.00 |
| Jun 30, 2024 | 227,000.00 |
| Mar 31, 2024 | 224,000.00 |
| Dec 31, 2023 | 649,000.00 |
| Sep 30, 2023 | 1.42 Mn |
| Jun 30, 2023 | 426,000.00 |
| Mar 31, 2023 | 408,000.00 |
| Dec 31, 2022 | 414,000.00 |
| Sep 30, 2022 | 1.42 Mn |
| Jun 30, 2022 | 354,000.00 |
| Mar 31, 2022 | 346,000.00 |
| Dec 31, 2021 | 336,000.00 |
| Sep 30, 2021 | 1.51 Mn |
| Jun 30, 2021 | 317,000.00 |
| Mar 31, 2021 | 308,000.00 |
| Dec 31, 2020 | 974,000.00 |
| Sep 30, 2020 | 1.48 Mn |
| Jun 30, 2020 | 1.06 Mn |
| Mar 31, 2020 | 1.04 Mn |
| Dec 31, 2019 | 1.68 Mn |
| Sep 30, 2019 | 1.48 Mn |
| Jun 30, 2019 | 3.26 Mn |
| Mar 31, 2019 | 1.92 Mn |
| Dec 31, 2018 | 1.95 Mn |
| Sep 30, 2018 | 1.63 Mn |
| Jun 30, 2018 | 1.49 Mn |
| Mar 31, 2018 | 199,000.00 |
| Dec 31, 2017 | 2.39 Mn |
| Sep 30, 2017 | 762,000.00 |
| Jun 30, 2017 | 172,000.00 |
| Mar 31, 2017 | 162,000.00 |
| Dec 31, 2016 | 1.26 Mn |
| Sep 30, 2016 | 159,000.00 |
| Jun 30, 2016 | 668,000.00 |
| Mar 31, 2016 | 1.38 Mn |
| Dec 31, 2015 | 117,000.00 |
| Sep 30, 2015 | 1.71 Mn |
| Jun 30, 2015 | 98,000.00 |
| Mar 31, 2015 | 91,000.00 |
| Dec 31, 2014 | 238,000.00 |
| Sep 30, 2014 | 229,000.00 |
| Jun 30, 2014 | 1.68 Mn |
| Mar 31, 2014 | 1.62 Mn |
| Dec 31, 2013 | 186,000.00 |
| Sep 30, 2013 | 359,000.00 |
| Jun 30, 2013 | 1.78 Mn |
| Mar 31, 2013 | 433,000.00 |
| Sep 30, 2012 | 498,000.00 |